tbuckley/cabot-search huggingface dataset:
Abstract 416: B-Raf Loss Suppresses Extracellular-Regulated Kinase Activation and Cardiomyocyte Proliferation
Authors: Natasha N Chattergoon, Sara McCrohan, Kent L Thornburg, Philip Stork
Journal: Circulation Research (2015)

Objectives: The postnatal heart does not retain the proliferative capacity it had during fetal life. Unlike large mammals, murine cardiomyocytes (CM) continue to divide into the first week of life before terminal differentiation and binucleation. We hypothesized that B-Raf regulates ERK activation in newborn CM and that loss of B-Raf suppresses cyclin levels and reduced proliferation. To test this, we determined whether loss of B-Raf disrupts the ERK (extracellular-regulated kinase) cascade and impairs CM growth. Methods: CM specific knockout (KO) of B-Raf was generated using CRE/lox (floxed B-Raf x αMHC CRE) resulting in a truncated, unstable B-Raf and a null phenotype. KO mice (α-MHC-CRE / B-Raf lox/lox ) were compared to CRE negative / B-Raf lox/lox mice (wild type; WT). Hearts from 3d and 8d old pups were harvested for molecular analysis of B-Raf signaling and cell cycle markers. Hearts from 3d old pups were harvested and CMs isolated for culture using a trypsin/DNAse digestion. The cells were treated with Isoproterenol (Iso;10uM), forskolin (20uM), and IGF-1 (1ng/ml) for 15 min to determine if the loss of B-Raf results in reduced activation of ERK. Results: Heart weight to body weight (HW/BW) ratio was less in 3d KO versus 3d WT (n=50, p&lt;0.05). HW/BW ratio became greater in 8d KO; there was no difference in 3d and 8d HW/BW in WT animals. Baseline B-Raf and phosphorylated ERK levels were reduced in KO hearts (*p&lt;0.05). Cell cycle inhibitors p21 and p53 were increased in 3d KO hearts with decreased levels of all cyclins (p&lt;0.05). In 8d KO hearts, increased p21, p27, and p53 expression was accompanied with increased cyclin levels (p&lt;0.05). In vitro ERK activation was blunted in KO CMs by forskolin and Iso compared to IGF-1. Conclusions: ERK activation was suppressed in KO hearts resulting in smaller newborn hearts but which exceeded normal HW/BW by 8d. This is may represent premature hypertrophy as the proliferative period of CM development had ended. Cell cycle analysis supports reduced CM mitotis among 8d CM. Such early disturbances in normal CM growth may increase susceptibility for reduced cardiac function in the face of increased postnatal load stress.
Proportion of Never-Smoker Non–Small Cell Lung Cancer Patients at Three Diverse Institutions
Authors: Lorraine Pelosof, Chul Ahn, Ang Gao, Leora Horn, Alejandra Madrigales, Joan Cox, Dauphne McGavic, John D. Minna, Adi F. Gazdar, Joan Schiller
Journal: JNCI Journal of the National Cancer Institute (2016)

Approximately 10% to 15% of lung cancer cases in the United States occur in never smokers, but there has been much debate about whether this rate is increasing. To determine whether the proportion of never smokers among lung cancer cases is increasing, we conducted a retrospective study using registries from The University of Texas Southwestern Medical Center, Parkland Hospital, and Vanderbilt University.
Evaluation of Traditional and Novel Predictive Markers of Anemia Response to Recombinant Human Erythropoietin (rh-Epo) in Patients with Multiple Myeloma and Lymphoma: Emerging Role of Functional Iron Deficiency.
Authors: Eirini Katodritou, Matthaios Speletas, Dimitris Kapetanos, Kostas Zervas, Aikaterini Pavlitou, Elisabeth Georgiou, Ioannis Korantzis, Michael Sion, John Christakis
Journal: Blood (2004)
Chromophores in operative surgery: Current practice and rationalized development
Authors: Ernest A. Azzopardi, Siân-Eleri Owens, Maxwell Murison, Daniel Rees, M. Anne Sawhney, Lewis W. Francis, R. Sofia Rodrigues Teixeira, Marc Clement, R. Steven Conlan, Iain S. Whitaker
Journal: Journal of Controlled Release (2017)
Analysis of the GERCOR index in <i>KRAS</i> Exon2 WT patients with mCRC treated with salvage-line cetuximab-based chemotherapy: HGCSG0901.
Authors: Ayumu Hosokawa, Satoshi Yuki, Hiroshi Nakatsumi, Kazuteru Hatanaka, Yasushi Tsuji, Hiroyuki Okuda, Yasuo Takahashi, Jun Konno, Kazunori Eto, Yasuyuki Kawamoto, Norikazu Sonoda, Yasushi Sato, Mayuko Saito, Takuto Miyagishima, Shinichiro Ikeda, Koji Yoshizaki, Takahide Sasaki, Soh Saitoh, Yuh Sakata, Yoshito Komatsu
Journal: Journal of Clinical Oncology (2015)

781 Background: The GERCOR index (GI) based on performance status and serum LDH was reported to be useful to predict survival for patients with previously untreated mCRC. However, in the salvage setting, the validity of the GI has not been reported in patients treated with cetuximab (Cmab)-based chemotherapy. Methods: 269 patients with mCRC treated with Cmab contained chemotherapy were retrospectively registered from 27 centers in Japan. This analysis was included in the KRAS Exon2 wild type patients who were refractory to or intolerant of 5-FU / irinotecan/ oxaliplatin and were never administered anti-EGFR-antibody. Univariate and multivariate analysis for overall survival (OS) were performed using patient characteristics. Survival analyses were performed with the Kaplan-Meier method, log-rank test and the Cox proportional hazards model. The analysis was also designed to determine whether the GERCOR index could be extended to progression-free survival (PFS). Results: All data were available for prognostic categorization in 132 patients. Median OS and PFS were 9.8 and 4.3 months. The distribution and median OS / PFS for GI were as follows: low risk (L)(n = 28; 17.9/3.8 months), intermediate risk (I)(n = 52; 12.2/5.0 months), and high risk (H)(n = 52; 7.5/4.1 months). For OS, there was significant difference between L and H (p &lt; 0.001) and between I and H (p &lt; 0.001), but not between L and I (p = 0.076). For PFS, there was significant difference between I and H (p = 0.017), but not between L and I (p = 0.407), and between L and H (p = 0.222). In the Cox multivariate analysis, GI showed an independent prognostic impact (L vs. I ; HR 2.195, p=0.003 / L vs. H ; HR 4.028, p&lt;0.001), but not predictive impact (L vs. I ; HR 0.987, p=0.958 / L vs. H ; HR 1.314, p=0.268). Conclusions: In this analysis, GI might be a prognostic factor in salvage treatment with Cmab-based chemotherapy.
Activation - Recovery Intervals of 12-Lead Electro-cardiograms Before and After Catheter Ablation in Patients With Wolff-Parkinson-White Syndrome
Authors: Makoto Nonokawa, Makoto Hirai, Makoto Akahoshi, Yasuya Inden, Yukihiko Yoshida, Teruo Ito, Yumiko Yokoyama, Takahisa Sawada, Atsuya Shimizu, Yasunobu Takada, Shigeo Iino, Takahisa Kondo, Hidehiko Saito
Journal: Circulation (2001)
Interleukin-10(IL-10)1082-A and Tumor Necrosis Factor(TNF)-Alpha 238/308A Genotypes Are Associated with Earlier (Younger Than 55) Onset of Multiple Myeloma.
Authors: Meral Beksac, Merih Kizil, Ender A. Soydan, Esin Serbest, Klara Dalva
Journal: Blood (2004)
Secondary-care costs associated with lung cancer diagnosed at emergency hospitalisation in the United Kingdom
Authors: Martyn P T Kennedy, Peter S Hall, Matthew E J Callister
Journal: Thorax (2017)

Lung cancer diagnosis during emergency hospital admission has been associated with higher early secondary-care costs and lower longer-term costs than outpatient diagnoses. This retrospective cohort study analyses the secondary-care costs of 3274 consecutive patients with lung cancer. Patients diagnosed during emergency admissions incurred greater costs during the first month and had a worse prognosis compared with outpatient diagnoses. In patients who remained alive, costs after the first month were comparable between diagnostic routes. In addition to improving patient experience and outcome, strategies to increase earlier diagnosis may reduce the additional healthcare costs associated with this route to diagnosis.
Characteristics of the ground-glass opacity nodules showing growth during follow-up.
Authors: H. Matsuguma, A. Ui, N. Oohata, R. Nakahara, T. Kasai, Y. Kamiyama, S. Igarashi, K. Mori, T. Kodama, K. Yokoi
Journal: Journal of Clinical Oncology (2011)

7060 Background: The National Lung Screening Trial implemented in the United States demonstrated a significant reduction in lung cancer mortality by screening with computed tomography (CT). These findings will lead to a sharp increase in the use of CT, and consequently an increase in the detection of ground-glass opacity (GGO) nodules. Non-invasive methods, including follow-up with CT, in order to determine which nodules require invasive diagnostic strategies, should rapidly be defined. The aim of this study is to elucidate the characteristics of GGO nodules that show growth during follow-up with CT. Methods: Between 2000 and 2008, from our database of over 60,000 CT examinations, we identified 178 GGO nodules, which showed a GGO area greater than 20% and measured less than 2cm in diameter from 172 patients. We investigated the clinical characteristics and CT images of the GGO nodules in relation to changes of the GGO nodules during follow-up period. Results: The nodule sizes ranged from 4 to 20 mm, with a median of 11 mm. One hundred and fifteen nodules were observed to be pure GGO. Follow-up periods ranged from 1 to 111 months, with a mean of 26 months. During the follow up period, 20 nodules showed fading or shrinkage, 121 showed no change in size, and 37 showed growth of at least 2 mm in diameter. Growth ranged from 2 to 14 mm, with a means of 4 mm. Time to 2mm nodule growth curves were caliculated with Kaplan-Meier methods using nodules excluding those showed fading or shrinkage. The 2- and 5-year cumulative percentages of growth nodule were calculated to be 23% and 31%. According to the nodule size and proportion of GGO, these were 4% and 14% for nodules less than 10 mm, 25% and 34% for 10 to 14 mm, both 60% for greater than 14 mm, 13% and 18% for pure GGO, and 40% and 51% for mixed GGO. No pure GGO nodule smaller or equal to 7mm showed growth. Univariate analysis revealed that nodule size, proportion of GGO, age, gender, history of lung cancer, and smoking history were factors predicting growth. Multivariate analysis disclosed that nodule size is the only predictive factor. Conclusions: Follow-up with CT is effective in the selection of patients who require further examination. Size of GGO nodule was strongly associated with the growth of GGO nodule during the follow-up.
Evidence of Effect Modification of Graft-Versus-Leukemia Effect of Cytomegalovirus By Alemtuzumab in Myeloid Malignancies Undergoing Unrelated Donor Transplantation
Authors: Mohamed Shanavas, Jieun Uhm, Naheed Alam, Eshetu G Atenafu, John Kuruvilla, Jeffrey H. Lipton, Hans A. Messner, Matthew Seftel, Vikas Gupta, Dennis Kim
Journal: Blood (2014)
Deficient stratum corneum intercellular lipid in a Japanese patient with lamellar ichthyosis with a homozygous deletion mutation in <i> <scp>SDR</scp> 9C7 </i>
Authors: T. Takeichi, T. Nomura, H. Takama, M. Kono, K. Sugiura, D. Watanabe, H. Shimizu, M.A. Simpson, J.A. McGrath, M. Akiyama
Journal: British Journal of Dermatology (2017)

Autosomal recessive congenital ichthyosis (ARCI) is an umbrella term for inherited non-syndromic ichthyosis, which includes harlequin ichthyosis, lamellar ichthyosis (LI), congenital ichthyosiform erythroderma and pleomorphic ichthyosis (also called self-healing/self-improving collodion baby).1 The clinical diversity is matched by genetic heterogeneity, with 11 genes currently implicated in the pathobiology of ARCI,2,3 including the most recent discovery of two missense mutations in SDR9C7 in three consanguineous Lebanese families.4 Here, we describe a case of ARCI (LI phenotype) that has a previously unreported homozygous deletion mutation in SDR9C7. We extend the spectrum of clinical features associated with SDR9C7 mutations, and identify deficient intercellular lipid and malformation of intercellular lipid layers in the stratum corneum.

This article is protected by copyright. All rights reserved.
Cellular accumulation of auristatins delivered via antibody targeting
Authors: Nicole M. Okeley, Charles G. Cerveny, Stephen C. Alley, Dennis Benjamin, Peter D. Senter
Journal: Cancer Research (2006)

Proc Amer Assoc Cancer Res, Volume 47, 2006

1982 

Monomethyl auristatin E and F (MMAE and MMAF), analogs of the antimitotic agent Dolastatin 10, are potent cytotoxic agents with IC50 values in the nM range. The cytotoxic activity of MMAF, possessing a charged phenylalanine at the C -terminus of the peptide, is attenuated compared to MMAE, which has an uncharged norephedrine at the C -terminus. It has been assumed that impaired cellular access is responsible for the attenuation of MMAF cytotoxicity. We have previously described the potent and highly selective in vitro and in vivo activities of antibody drug conjugates (ADCs) consisting of the chimeric anti-CD30 monoclonal antibody cAC10 linked to MMAE and MMAF. When these drugs are attached to an antibody via a maleimidocaproyl moiety with a protease-sensitive valine-citrulline dipeptide linkage connected to a self-immolative p -aminobenzylcarbamate spacer (vc linker), both are highly potent, with IC50 values in the ng/mL range. Even if the linkage is simplified to the maleimidocaproyl moiety alone (mc linker), MMAF ADCs retain cytotoxicity. To understand the origin of the differential activity between free drugs and ADCs, the concentrations of drugs liberated within treated cells by internalized ADCs were measured. Many typical procedures used to study intracellular drug concentrations use radio-isotopically labeled drugs, however examination of ADCs requires an additional level of complexity in the experimental procedure in order to address ADC-bound vs. liberated drug. With radio-isotopically labeled versions of the vcMMAE, vcMMAF, and mcMMAF drug linkers in hand, we have devised a procedure utilizing a cell surface stripping step and a protein precipitation step to investigate intracellular ADC metabolism. We have shown that drugs are rapidly released from cAC10 ADCs once internalized into CD30+ cells and that intracellular drug concentrations can reach upwards of 1 μM. Those cells with higher IC50 values for some ADCs but lower values for others achieve lower intracellular concentrations of liberated drug in the case of the less potent ADC. Thus there is a correlation between intracellular drug concentration and cell sensitivity, indicating that there may be a threshold concentration above which a cell will become sensitive to an auristatin-antibody conjugate.
Clinical Outcomes of Acute Promyelocytic Leukemia (APL) Patients According to FLT3 Mutation Status
Authors: Harshabad Singh, Lillian Werner, Daniel J DeAngelo, Philip C. Amrein, Martha Wadleigh, Karen K Ballen, Edward Fox, Ilene Galinsky, Donna Neuberg, Richard M Stone, Eyal C Attar
Journal: Blood (2010)
Idiotype Vaccination of Untreated Indolent B-Cell Lymphoma: Durable Objective Remissions and Association of Superior Outcome with Cellular Immune Responses
Authors: Marcelo A. Navarrete, Kristina Heining-Mikesch, Cristina Bertinetti-Lapatki, Marcus Duehren-von Minden, Andrea Hafkemeyer, Hendrik Veelken
Journal: Blood (2008)
Monocytosis in Polycythemia Vera: Clinical and Molecular Correlates
Authors: Daniela Barraco, Sonia Cerquozzi, Naseema Gangat, Mrinal M Patnaik, Terra L. Lasho, Christy Finke, Curtis A. Hanson, Rhett P. Ketterling, Animesh Pardanani, Ayalew Tefferi
Journal: Blood (2016)
Acquired Extramedullary Resistance to Dasatinib Due to Selection of Philadelphia-Positive Lymphoblast Clone Harboring a T315I BCR-ABL Gene Mutation: Reversal by Dose Escalation and Hydroxyurea.
Authors: Tuija Lundan, Franz Gruber, Martin Hoglund, Bengt Simonsson, Sakari Knuutila, Kimmo Porkka
Journal: Blood (2005)
Presence of DRB1*01 Allele in Multiple Myeloma Patients Is Associated with Indolent Disease.
Authors: M. Alcoceba, L. Marin, A. Balanzategui, M.E. Sarasquete, P. Martin-Jimenez, M.C. Chillon, M. Vargas, R. Corral, E. Perez, J. Fernandez-Calvo, A. Martinez, J.M. Hernandez, Joan Blade, J.J. Lahuerta, R. Garcia-Sanz, M. Gonzalez, J.F. San Miguel
Journal: Blood (2007)
Individuals with mutations in XPNPEP3, which encodes a mitochondrial protein, develop a nephronophthisis-like nephropathy
Authors: John F. O’Toole, Yangjian Liu, Erica E. Davis, Christopher J. Westlake, Massimo Attanasio, Edgar A. Otto, Dominik Seelow, Gudrun Nurnberg, Christian Becker, Matti Nuutinen, Mikko Kärppä, Jaakko Ignatius, Johanna Uusimaa, Salla Pakanen, Elisa Jaakkola, Lambertus P. van den Heuvel, Henry Fehrenbach, Roger Wiggins, Meera Goyal, Weibin Zhou, Matthias T.F. Wolf, Eric Wise, Juliana Helou, Susan J. Allen, Carlos A. Murga-Zamalloa, Shazia Ashraf, Moumita Chaki, Saskia Heeringa, Gil Chernin, Bethan E. Hoskins, Hassan Chaib, Joseph Gleeson, Takehiro Kusakabe, Takako Suzuki, R. Elwyn Isaac, Lynne M. Quarmby, Bryan Tennant, Hisashi Fujioka, Hannu Tuominen, Ilmo Hassinen, Hellevi Lohi, Judith L. van Houten, Agnes Rotig, John A. Sayer, Boris Rolinski, Peter Freisinger, Sethu M. Madhavan, Martina Herzer, Florence Madignier, Holger Prokisch, Peter Nurnberg, Peter K. Jackson, Hemant Khanna, Nicholas Katsanis, Friedhelm Hildebrandt
Journal: Journal of Clinical Investigation (2010)

During the preparation of
Combination of c-SRC and FLT3 Inhibitors Has An Additive Inhibitory Effect on FLT3 ITD but Not on FLT3 TKD Positive Cells
Authors: Hannes Leischner, Rebekka Grundler, Corinna Albers, Anna Lena Illert, Katharina Götze, Christian Peschel, Justus Duyster
Journal: Blood (2010)
PRT064445 but Not Recombinant Fviia Reverses Rivaroxaban Induced Anticoagulation As Measured by Reduction in Blood Loss in a Rabbit Liver Laceration Model
Authors: Stanley J Hollenbach, Genmin Lu, Siusze Tan, Gail Lee, Hutchaleelaha Athiwat, Mayuko Inagaki, Uma Sinha
Journal: Blood (2012)
Hospitals struggle to integrate physical and mental healthcare, inquiry finds
Authors: Susan Mayor
Journal: BMJ (2017)

Hospitals find it difficult to integrate physical and mental healthcare in people with mental health conditions who are admitted with a physical illness, an inquiry has found.1

Lesley Regan, chair of the National Confidential Enquiry into Patient Outcome and Death (NCEPOD), which carried out the review, explained, “This is the first time anyone has critically examined the way physicians and surgeons respond to the mental health disorders of patients admitted to acute general hospitals for management of their coexisting physical ill health.

“I suspect that many clinicians . . . will be surprised by the magnitude of the problem. Opportunities to identify patients with dual pathology are regularly missed. For example, only half of those patients who would have benefited from a referral to liaison psychiatry received one from the …
Aberrant Phosphorylation of SMAD4 Thr277-Mediated USP9x–SMAD4 Interaction by Free Fatty Acids Promotes Breast Cancer Metastasis
Authors: Yong Wu, Xiaoting Yu, Xianghua Yi, Ke Wu, Sami Dwabe, Mohammad Atefi, Yahya Elshimali, Kevin T. Kemp, Kruttika Bhat, Jesse Haro, Marianna Sarkissyan, Jaydutt V. Vadgama
Journal: Cancer Research (2017)

Abstract Obesity increases the risk of distant metastatic recurrence and reduces breast cancer survival. However, the mechanisms behind this pathology and identification of relevant therapeutic targets are poorly defined. Plasma free fatty acids (FFA) levels are elevated in obese individuals. Here we report that TGFβ transiently activates ERK and subsequently phosphorylates SMAD4 at Thr277, which facilitates a SMAD4–USP9x interaction, SMAD4 nuclear retention, and stimulates TGFβ/SMAD3–mediated transcription of Twist and Snail. USP9x inhibited the E3 ubiquitin-protein ligase TIF1γ from binding and monoubiquitinating SMAD4, hence maintaining the SMAD4 nuclear retention. FFA further facilitated TGFβ-induced ERK activation, SMAD4 phosphorylation, and nuclear retention, promoting TGFβ-dependent cancer progression. Inhibition of ERK and USP9x suppressed obesity-induced metastasis. In addition, clinical data indicated that phospho-ERK and -SMAD4 levels correlate with activated TGFβ signaling and metastasis in overweight/obese patient breast cancer specimens. Altogether, we demonstrate the vital interaction of USP9x and SMAD4 for governing TGFβ signaling and dyslipidemia-induced aberrant TGFβ activation during breast cancer metastasis. Cancer Res; 77(6); 1383–94. ©2017 AACR.
Toll-Like Receptor 2 and 4 Are Expressed on Transplanted T-Cell Subsets and Influence Outcome after Allogeneic Unrelated Peripheral Blood Stem Cell Transplantation.
Authors: Uwe Platzbecker, Jan Stoehlmacher, Eray Goekkurt, Caroline Pabst, Christian Thiede, Gerhard Ehninger, Martin Bornhäuser
Journal: Blood (2007)
Final Analysis of the ALFA 0701 Study
Authors: Sylvie Castaigne, Cécile Pautas, Christine Terré, Aline Renneville, Claude Gardin, Felipe Suarez, Denis Caillot, Céline Berthon, Philippe Rousselot, Claude Preudhomme, Laure Morisset, Karine Celli Lebras, Sylvie Chevret, Hervé Dombret
Journal: Blood (2014)
Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium
Authors: A M Zeidan, N Al Ali, J Barnard, E Padron, J E Lancet, M A Sekeres, D P Steensma, A DeZern, G Roboz, E Jabbour, G Garcia-Manero, A List, R Komrokji
Journal: Leukemia (2017)
High BMI in pregnancy does not cause obesity risk in offspring, study finds
Authors: Susan Mayor
Journal: BMJ (2017)

Having a high body mass index (BMI) during pregnancy is not associated with a long term risk of obesity in offspring, a UK longitudinal study has found.1

The findings suggest that public health measures to reduce obesity should focus on helping women achieve a healthy weight before and after pregnancy, the authors said, rather than putting undue emphasis on their weight during pregnancy.

Being overweight or …
Diabetes Care in Latinos With Limited English Proficiency
Authors: Jennifer Alvidrez, Eliseo J. Pérez-Stable
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Risk Factors and Risk Stratification for Adverse Obstetrical Outcomes After Appendectomy or Cholecystectomy During Pregnancy
Authors: Adam Sachs, Jean Guglielminotti, Russell Miller, Ruth Landau, Richard Smiley, Guohua Li
Journal: JAMA Surgery (2017)

Identification of risk factors for adverse obstetrical outcomes after appendectomy and cholecystectomy during pregnancy is necessary for evidence-based risk reduction and adequate patient counseling.